

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS:**

**Claims 1, 2, 16, and 17 have been amended as follows.**

**Claims 21 and 22 have been added.**

1. (Amended) An isolated [A purified] polypeptide comprising an amino acid sequence selected from the group consisting of:

- c) an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5,
- d) a naturally-occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of [SEQ ID NO:1,] SEQ ID NO:3[,] and SEQ ID NO:5,
- e) a biologically-active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5, [and]
- f) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5, and
- g) a naturally-occurring amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO:1.

2. (Amended) An isolated polypeptide of claim 1, comprising [having a] an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5.

16. (Amended) A [pharmaceutical] composition comprising an [effective amount of] a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

17. (Amended) A [pharmaceutical] composition of claim 16, wherein the polypeptide comprises [has] an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5.